中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2014年
8期
508-511
,共4页
冯沿芬%符珈%颜淑梅%凌逸虹%黄奕莉%蔡木炎%饶慧兰
馮沿芬%符珈%顏淑梅%凌逸虹%黃奕莉%蔡木炎%饒慧蘭
풍연분%부가%안숙매%릉일홍%황혁리%채목염%요혜란
淋巴瘤,T细胞,外周%杀伤细胞,天然%抗原,CD30
淋巴瘤,T細胞,外週%殺傷細胞,天然%抗原,CD30
림파류,T세포,외주%살상세포,천연%항원,CD30
Lymphoma,T-cell,peripheral%Killer cells,natural%Antigens,CD30
目的 统计中山大学肿瘤防治中心4年间诊断的所有成熟T和自然杀伤(NK)细胞淋巴瘤病例,分析其不同类型的构成比,研究各类型成熟T和NK细胞淋巴瘤CD30表达情况,为抗CD30抗体药物在成熟T和NK细胞淋巴瘤的应用提供参考数据.方法 选取2009年9月1日至2013年8月31日4年间中山大学肿瘤防治中心诊断的所有成熟T和NK细胞淋巴瘤,统计分析各类型淋巴瘤的发病情况.抽调其中存档的164例成熟T和NK细胞淋巴瘤患者的病理蜡块进行免疫组织化学EnVision法检测其CD30的表达.结果 4年间共诊断成熟T和NK细胞淋巴瘤625例.最常见为结外鼻型NK/T细胞淋巴瘤(ENKTL),共319例(51.0%),其余常见病例分别为血管免疫母细胞性T细胞淋巴瘤(AITL) 119例(19.0%)、非特指型外周T细胞淋巴瘤(PTCL-NOS)81例(13.0%)、间变性大细胞淋巴瘤(ALCL)[包括系统性ALCL 48例(7.7%)及原发皮肤ALCL 11例(1.8%)].除ALCL外,在本院存档的164例病例中,CD30阳性率最高的是NK/T细胞淋巴瘤,阳性率为62.1%(41/66).16例PTCL-NOS仅1例阳性,其余28例AITL及其他少见类型的淋巴瘤无1例阳性.结论 中山大学肿瘤防治中心收集的成熟T和NK细胞淋巴瘤不同类型的发病情况各异.CD30在多种成熟T和NK细胞淋巴瘤中均有不同程度表达,除间变性大细胞淋巴瘤,NK/T细胞淋巴瘤的阳性表达率最高,有望成为抗CD30抗体药物治疗的候选病种.
目的 統計中山大學腫瘤防治中心4年間診斷的所有成熟T和自然殺傷(NK)細胞淋巴瘤病例,分析其不同類型的構成比,研究各類型成熟T和NK細胞淋巴瘤CD30錶達情況,為抗CD30抗體藥物在成熟T和NK細胞淋巴瘤的應用提供參攷數據.方法 選取2009年9月1日至2013年8月31日4年間中山大學腫瘤防治中心診斷的所有成熟T和NK細胞淋巴瘤,統計分析各類型淋巴瘤的髮病情況.抽調其中存檔的164例成熟T和NK細胞淋巴瘤患者的病理蠟塊進行免疫組織化學EnVision法檢測其CD30的錶達.結果 4年間共診斷成熟T和NK細胞淋巴瘤625例.最常見為結外鼻型NK/T細胞淋巴瘤(ENKTL),共319例(51.0%),其餘常見病例分彆為血管免疫母細胞性T細胞淋巴瘤(AITL) 119例(19.0%)、非特指型外週T細胞淋巴瘤(PTCL-NOS)81例(13.0%)、間變性大細胞淋巴瘤(ALCL)[包括繫統性ALCL 48例(7.7%)及原髮皮膚ALCL 11例(1.8%)].除ALCL外,在本院存檔的164例病例中,CD30暘性率最高的是NK/T細胞淋巴瘤,暘性率為62.1%(41/66).16例PTCL-NOS僅1例暘性,其餘28例AITL及其他少見類型的淋巴瘤無1例暘性.結論 中山大學腫瘤防治中心收集的成熟T和NK細胞淋巴瘤不同類型的髮病情況各異.CD30在多種成熟T和NK細胞淋巴瘤中均有不同程度錶達,除間變性大細胞淋巴瘤,NK/T細胞淋巴瘤的暘性錶達率最高,有望成為抗CD30抗體藥物治療的候選病種.
목적 통계중산대학종류방치중심4년간진단적소유성숙T화자연살상(NK)세포림파류병례,분석기불동류형적구성비,연구각류형성숙T화NK세포림파류CD30표체정황,위항CD30항체약물재성숙T화NK세포림파류적응용제공삼고수거.방법 선취2009년9월1일지2013년8월31일4년간중산대학종류방치중심진단적소유성숙T화NK세포림파류,통계분석각류형림파류적발병정황.추조기중존당적164례성숙T화NK세포림파류환자적병리사괴진행면역조직화학EnVision법검측기CD30적표체.결과 4년간공진단성숙T화NK세포림파류625례.최상견위결외비형NK/T세포림파류(ENKTL),공319례(51.0%),기여상견병례분별위혈관면역모세포성T세포림파류(AITL) 119례(19.0%)、비특지형외주T세포림파류(PTCL-NOS)81례(13.0%)、간변성대세포림파류(ALCL)[포괄계통성ALCL 48례(7.7%)급원발피부ALCL 11례(1.8%)].제ALCL외,재본원존당적164례병례중,CD30양성솔최고적시NK/T세포림파류,양성솔위62.1%(41/66).16례PTCL-NOS부1례양성,기여28례AITL급기타소견류형적림파류무1례양성.결론 중산대학종류방치중심수집적성숙T화NK세포림파류불동류형적발병정황각이.CD30재다충성숙T화NK세포림파류중균유불동정도표체,제간변성대세포림파류,NK/T세포림파류적양성표체솔최고,유망성위항CD30항체약물치료적후선병충.
Objective To investigate the frequency of different types of mature T-and NK-cell lymphomas diagnosed in a 4-year period at Sun Yat-sen University Cancer Center,and to study baseline CD30 for potential anti-CD30 targeted therapy in mature T-and NK-cell lymphoma.Methods All cases of mature T-and NK-cell lymphoma diagnosed at Sun Yat-sen University Cancer Center from September 1,2009 to August 31,2013,were reviewed.Paraffin-blocks of available 164 consecutive cases were stained for CD30 immunohistochemistry using EnVision protocol.Results A total of 625 cases of mature T-and NK-cell lymphomas were diagnosed and the most common type was extranodal NK/T cell lymphoma (ENKTL),nasal type 319 (51.0%) cases,followed by angioimmunoblastic T-cell lymphoma (AITL) (119 cases,19.0%),peripheral T-cell lymphoma,not otherwise specified (PTCL-NOS) (81 cases,13.0%),and anaplastic large-cell lymphoma (ALCL),including 48 cases (7.7%) of systematic ALCL and 11 cases(1.8%) of primary cutaneous ALCL.Besides ALCL,ENKTL had the highest expression rate of CD30 among the 164 cases,with positivity observed in 41 cases (62.1%,41/66).Only 1 case of PTCL-NOS was CD30 positive.CD30 was not expressed in all 28 cases of AITL and other rare types of mature T-and NK-cell lymphoma.Conclusions The frequency of different types of mature T-and NK-cell lymphoma encountered at Sun Yat-sen University Cancer Center was similar to that seen in other areas of China and other Asia countries.CD30 expression is different among several types of mature T-and NK-cell lymphoma.In addition to ALCL,ENKTL has the highest expression rate of CD30,which may be a candidate disease for anti-CD30 targeted therapy.